^ ab“The tuberin-hamartin complex negatively regulates beta-catenin signaling activity”. The Journal of Biological Chemistry278 (8): 5947–51. (February 2003). doi:10.1074/jbc.C200473200. PMID12511557.
^ ab“Interaction of FoxO1 and TSC2 induces insulin resistance through activation of the mammalian target of rapamycin/p70 S6K pathway”. The Journal of Biological Chemistry281 (52): 40242–51. (December 2006). doi:10.1074/jbc.M608116200. PMID17077083.
^“TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth”. Cell126 (5): 955–68. (September 2006). doi:10.1016/j.cell.2006.06.055. PMID16959574.
^“Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis”. Cell121 (2): 179–93. (April 2005). doi:10.1016/j.cell.2005.02.031. PMID15851026.
^“Association of focal adhesion kinase with tuberous sclerosis complex 2 in the regulation of s6 kinase activation and cell growth”. The Journal of Biological Chemistry281 (49): 37321–9. (December 2006). doi:10.1074/jbc.M605241200. PMID17043358.
^“Pam and its ortholog highwire interact with and may negatively regulate the TSC1.TSC2 complex”. The Journal of Biological Chemistry279 (2): 1351–8. (January 2004). doi:10.1074/jbc.M310208200. PMID14559897.
^ ab“Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner”. The Journal of Biological Chemistry278 (35): 32493–6. (August 2003). doi:10.1074/jbc.C300226200. PMID12842888.
^“Multicompartmental distribution of the tuberous sclerosis gene products, hamartin and tuberin”. Archives of Biochemistry and Biophysics404 (2): 210–7. (August 2002). doi:10.1016/S0003-9861(02)00300-4. PMID12147258.
^“Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins”. Nature Cell Biology5 (6): 578–81. (June 2003). doi:10.1038/ncb999. PMID12771962.
^“Human papillomavirus 16 E6 oncoprotein interferences with insulin signaling pathway by binding to tuberin”. The Journal of Biological Chemistry279 (34): 35664–70. (August 2004). doi:10.1074/jbc.M403385200. PMID15175323.
^“Identification and characterization of the interaction between tuberin and 14-3-3zeta”. The Journal of Biological Chemistry277 (42): 39417–24. (October 2002). doi:10.1074/jbc.M204802200. PMID12176984.
“Tuberous sclerosis complex genes: from flies to human genetics”. Archives of Dermatological Research293 (8): 383–6. (August 2001). doi:10.1007/s004030100250. PMID11686512.
“Aspects of tuberous sclerosis complex (TSC) protein function in the brain”. Biochemical Society Transactions31 (Pt 3): 579–83. (June 2003). doi:10.1042/BST0310579. PMID12773159.
“Tuberous sclerosis complex (TSC) gene involvement in sporadic tumours”. Biochemical Society Transactions31 (Pt 3): 597–602. (June 2003). doi:10.1042/BST0310597. PMID12773163.
“Growth control under stress: mTOR regulation through the REDD1-TSC pathway”. Cell Cycle4 (11): 1500–02. (November 2005). doi:10.4161/cc.4.11.2139. PMID16258273.
“Giant cells: contradiction to two-hit model of tuber formation?”. Cellular and Molecular Neurobiology27 (2): 251–61. (March 2007). doi:10.1007/s10571-006-9106-0. PMID16897363.
“TSC2, a key player in tumor suppression and cystic kidney disease”. Nephrologie & Therapeutique2 Suppl 2: S119-22. (January 2006). PMID17373211.
“[Pulmonary lymphangioleiomyomatosis with or without tuberous sclerosis]”. Revue des Maladies Respiratoires24 (6): 725–40. (June 2007). doi:10.1016/S0761-8425(07)91147-X. PMID17632432.